Why the study?
Traditional cardiovascular disease management uses a uniform one-size-fits-all approach, whereas precision medicine aims to tailor therapies by identifying endotypes with different underlying pathophysiology.
Answers are grounded in this paper and cite their sources.
This review highlights the potential of precision medicine, utilizing biomarkers and intravascular assessment, to tailor treatments for patients with acute and chronic coronary syndromes.
The traditional approach to management of cardiovascular disease relies on grouping clinical presentations with common signs and symptoms into pre-specified disease pathways, all uniformly treated according to evidence-based guidelines ("one-size-fits-all"). The goal of precision medicine is to provide the right treatment to the right patients at the right time, combining data from time honoured sources (e.g., history, physical examination, imaging, laboratory) and those provided by multi-omics technologies. In patients with ischemic heart disease, biomarkers and intravascular assessment can be used to identify endotypes with different pathophysiology who may benefit from distinct treatments. This review discusses strategies for the application of stratified management to patients with acute and chronic coronary syndromes.
No takes yet. Share an insight, caveat, or question.
Montone et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: